Document:

EX-4.6

 Exhibit 4.6 

Schedule of Holders of 
 Warrants
to Purchase Preferred Stock 
  

																					
	 Holder
	  	Number of
Shares	 	  	Exercise
Price	 	  	Issuance
Date	 	  	Expiration
Date	 	  	Conversion
Shares	 
	 Maxim Partners LLC
	  	 	316,373	 	  	$	2.01	 	  	 	12/18/2013	 	  	 	12/17/2018	 	  	 	Series B Preferred	 
	 Maxim Partners LLC
	  	 	119,749	 	  	$	2.01	 	  	 	01/22/2014	 	  	 	01/21/2019	 	  	 	Series B Preferred	 
	 Maxim Partners LLC
	  	 	122,126	 	  	$	2.01	 	  	 	02/28/2014	 	  	 	02/27/2019	 	  	 	Series B Preferred	 
	 Maxim Partners LLC
	  	 	61,066	 	  	$	2.01	 	  	 	05/16/2014	 	  	 	05/15/2019	 	  	 	Series B Preferred	 
	 Maxim Partners LLC
	  	 	786,805	 	  	$	1.98	 	  	 	12/30/2016	 	  	 	12/29/2021	 	  	 	Series C Preferred	 
	 Maxim Partners LLC
	  	 	558,840	 	  	$	1.98	 	  	 	12/30/2016	 	  	 	12/29/2021	 	  	 	Series C Preferred	 
	 Maxim Partners LLC
	  	 	8,333	 	  	$	1.98	 	  	 	04/28/2017	 	  	 	04/27/2022	 	  	 	Series C Preferred	 

 THE WARRANT REPRESENTED HEREBY AND THE SERIES      CONVERTIBLE PREFERRED STOCK
HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), OR ANY STATE SECURITIES LAWS AND NEITHER THIS WARRANT NOR THE SERIES      CONVERTIBLE PREFERRED STOCK NOR ANY INTEREST
THEREIN MAY BE TRANSFERRED IN THE ABSENCE OF SUCH REGISTRATION OR AN EXEMPTION THEREFROM UNDER SUCH SECURITIES ACT AND SUCH LAWS AND THE RULES AND REGULATIONS THEREUNDER. THE SERIES      CONVERTIBLE PREFERRED STOCK
ISSUABLE UPON THE EXERCISE OF THIS WARRANT IS SUBJECT TO THE PROVISIONS OF A STOCKHOLDERS AGREEMENT, DATED AS OF THE DATE HEREOF, AS MAY BE AMENDED FROM TIME TO TIME (A COPY OF WHICH ARE ON FILE WITH THE SECRETARY OF THE COMPANY), AND MAY NOT BE
SOLD, TRANSFERRED, ASSIGNED, PLEDGED, HYPOTHECATED OR OTHERWISE DISPOSED OF EXCEPT IN COMPLIANCE WITH THE PROVISIONS OF SUCH STOCKHOLDERS AGREEMENT. 

Warrant Certificate No.          

Dated:
                                 

SERIES      CONVERTIBLE PREFERRED STOCK WARRANT 

CENTREXION CORPORATION 

THIS IS TO CERTIFY THAT for value received, MAXIM PARTNERS LLC (the “Holder’) is entitled, subject to the terms and conditions set
forth below, to purchase from Centrexion Corporation, a Delaware corporation (the “Company”),
                                        
                    
                                         
                                       
(                ) shares (the “Warrant Shares”) of Series      Convertible Preferred Stock, par value $0.001 per share, of
the Company (“Series      Preferred Stock”), at a price per share equal to $2.01 (the “Exercise Price”). This warrant (this “Warrant”) is being issued pursuant to the Placement Agency
Agreement, dated October 14,2013 (the “Placement Agency Agreement”), by and between Maxim Partners LLC and the Company. All Warrant Shares issued under this Warrant pursuant to the Placement Agency Agreement are referred to herein,
collectively, as the “Warrants.” 
 1. Manner of Exercise; Expiration Date. 

(a) This Warrant shall be exercisable in accordance with this Section 1 and Section 2 below from and after the date hereof until 5:00
p.m., New York time on the fifth (5th) anniversary of the date hereof (the “Exercise Period”). The Holder may from time to time during the Exercise Period on any business day exercise
this Warrant, for all or any part of the Warrant Shares purchasable at such time hereunder, by delivering to the Company at its principal office (i) a written notice of the Holder’s election to exercise this Warrant (an “Exercise
Notice”), which Exercise Notice shall be irrevocable and shall specify the number of Warrant Shares to be purchased, (ii) payment of the aggregate Exercise Price for the applicable number of Warrant Shares to be purchased by check or wire
transfer of immediately available funds to an account then specified by the Company and (iii) this Warrant (the date on which the foregoing items are delivered to the Company being hereinafter referred to as the “Exercise Date”). Such
Exercise Notice shall be in the form of Annex A hereto, duly executed by the Holder or its duly authorized agent. 
 (b) Upon receipt
of the items specified in Section 1 (a), the Company shall execute (or cause to be executed) and deliver (or cause to be delivered) to the Holder a certificate or certificates representing the aggregate number of full Warrant Shares issuable
upon such exercise. This Warrant shall be deemed to have been exercised and such certificate or certificates shall be deemed to have been issued, and the Holder shall be deemed to have become a Holder of record of such shares for all purposes, as of
the Exercise Date. 

 (c) If this Warrant is exercised in part, the Company shall, at the time of delivery of the
certificate or certificates representing the Warrant Shares being issued, deliver to the Holder a new Warrant evidencing the rights of the Holder to purchase the unpurchased Warrant Shares called for by this Warrant. Such new Warrant shall in all
other respects be identical to this Warrant. 
 (d) The Company shall pay any and all issue and other taxes (other than income taxes) that
may be payable in respect of the issuance of this Warrant or any issuance or delivery of Warrant Shares on exercise of this Warrant; provided, however, that the Company shall not be obligated to pay any transfer taxes resulting from any transfer
requested by the Holder of record of this Warrant in connection with any such exercise. 
 (e) The Company shall at all times reserve and
keep available out of its authorized but unissued shares of capital stock, solely for the purpose of effecting the exercise of this Warrant, such number of its shares of capital stock as shall from time to time be sufficient to effect such exercise
of this Warrant for the maximum number of shares of such class or series of capital stock issuable upon exercise of this Warrant; and if at any time the number of authorized but unissued shares of such capital stock shall not be sufficient to effect
such exercise of this Warrant for the maximum number of shares of such capital stock then issuable upon exercise hereunder, the Company will take such corporate action as may, in the opinion of its counsel, be necessary to increase its authorized
but unissued shares of such capital stock to such number of shares as shall be sufficient for such purpose, including, without limitation, engaging in best efforts to obtain the requisite stockholder approval of any necessary amendment to the
Company’s Certificate of Incorporation (as amended from time to time). The Company will not at any time close its stock transfer books in a manner which prevents the timely exercise of this Warrant. 

(f) If the Holder has not exercised this Warrant prior to the closing of a Corporate Transaction (as defined below) or in connection with a
Corporation Transaction as provided in Section 12, this Warrant shall automatically be deemed to be exercised in full in the manner set forth in Section 2, without any further action on behalf of the Holder, immediately prior to such
closing. In such case, if the fair market value of one share of Series      Preferred Stock is less than the Exercise Price (at the date of calculation as set forth in Section 2), this Warrant will be deemed to be
terminated without any further payment. “Corporate Transaction’’ shall mean (A) the closing of the sale, transfer or other disposition of all or substantially all of the Company’s assets, (B) the consummation of
the merger or consolidation of the Company with or into another entity (except a merger or consolidation in which the holders of capital stock of the Company immediately prior to such merger or consolidation continue to hold at least 50% of the
voting power of the capital stock of the Company or the surviving or acquiring entity), (C) the closing of the transfer (whether by merger, consolidation or otherwise), in one transaction or a series of related transactions, to a person or group of
affiliated persons (other than an underwriter of this corporation’s securities), of the Company’s securities if, after such closing, such person or group of affiliated persons would hold 50% or more of the outstanding voting stock of this
corporation (or the surviving or acquiring entity), (D) an Initial Public Offering (as defined below) of the Company or (E) a liquidation, dissolution or winding up of this corporation; provided, however, that a transaction shall not constitute
a Corporate Transaction if its sole purpose is to change the state of the Company’s incorporation or to create a holding company that will be owned in substantially the same proportions by the persons who held the Company’s securities
immediately prior to such transaction. Notwithstanding the prior sentence, the sale of shares of the Company’ s preferred stock in a bona fide financing transaction shall not be deemed a “Corporate Transaction. 

2. Net Exercise Issue. Notwithstanding any provision herein to the contrary, if the fair market value of one share of
Series      Preferred Stock is greater than the Exercise Price (at the date of calculation as set forth below), in lieu of exercising this Warrant for cash, the Holder may elect to receive shares equal to the value
(as determined below) of this Warrant (or the portion thereof being canceled) by surrender of this Warrant at the principal office of the Company together with the properly endorsed Exercise Notice in which event the Company shall issue to the
Holder a number of shares of Series      Preferred Stock computed using the following formula: 

  
 2 

 X = Y (A-B) 

A 
 Where
X     =     the number of Warrant Shares to be issued to the Holder 
  

	 	Y	 =     the number of Warrant Shares with respect to which this Warrant is being exercised

  

	 	A	 =     the fair market value of one share of Series     
Preferred Stock (at the date of such calculation) 

  

	 	B	 =     Exercise Price (as adjusted to the date of such calculation) 

For purposes of the above calculation, the fair market value of one share of Series      Preferred Stock shall be
equal to $1.75, or, if the Company has consummated any other financing in which the Company issues capital stock of the Company in exchange for cash, the price per share of such capital stock (on an as-
converted basis to Common Stock, par value $0.01 per share, of the Company (“Common Stock”)) sold in the latest financing; except that, if the Company has consummated a sale of shares of its equity securities in a bona fide
firm commitment underwritten public offering pursuant to a registration statement on Form S-1 (or a successor form) under the Securities Act (an “Initial Public Offering’’), then the Series
     Preferred Stock (on an as-converted basis to Common Stock) and the Common Stock shall be valued at the volume weighted average price of the Common Stock for the 30 trading days
immediately prior to the Exercise Date, as reported by Bloomberg. 
 3. Adjustment of Exercise Price and Number of Conversion Shares.

 (a) Adjustments for Stock Dividends, Splits, etc. If the Company declares or pays a dividend on the outstanding shares of the
Series      Preferred Stock or other securities, then upon exercise of this Warrant, for each Warrant Share acquired, Holder shall receive, without cost to Holder, the total number and kind of securities to which
Holder would have been entitled had Holder owned the Warrant Shares of record as of the date the dividend occurred. If the Company subdivides the outstanding shares of Series      Preferred Stock by reclassification
or otherwise into a greater number of shares, the number of Warrant Shares purchasable hereunder shall be proportionately increased and the Warrant Price shall be proportionately decreased. If the outstanding shares of
Series      Preferred Stock are combined or consolidated, by reclassification or otherwise, into a lesser number of shares, the Warrant Price shall be proportionately increased and the number of Warrant Shares shall
be proportionately decreased. 
 (b) Reclassification. Reorganization and Consolidation. In case of any reclassification, capital
reorganization or change in the capital stock of the Company, then, as a condition of such reclassification, reorganization or change, lawful provision shall be made, and duly executed documents evidencing the same from the Company or its successor
shall be delivered to the Holder, so that the Holder shall have the right at any time prior to the expiration of this Warrant to purchase, at a total price equal to that payable upon the exercise of this Warrant, the kind and amount of shares of
stock and other securities or property receivable in connection with such reclassification, reorganization or change by a holder of the same number and type of securities as were purchasable as Warrant Shares by the Holder immediately prior to such
reclassification, reorganization or change. In any such case appropriate provisions shall be made with respect to the rights and interest of the Holder so that the provisions hereof shall thereafter be applicable with respect to any shares of stock
or other securities or property deliverable upon exercise hereof, and appropriate adjustments shall be made to the Exercise Price per Warrant Share payable hereunder, provided the aggregate Exercise Price shall remain the same. 

  
 3 

 4. Fractional Shares. No fractional Warrant Shares shall be issuable upon exercise or
conversion of the Warrant and the number of Warrant Shares to be issued shall be rounded up to the nearest whole Warrant Share. 
 5.
Replacement of Warrant. On receipt of evidence reasonably satisfactory to the Company of the loss, theft, destruction or mutilation of this Warrant and, in the case of any such loss, theft or destruction of this Warrant, on delivery of an
indemnity agreement reasonably satisfactory in form and amount to the Company or, in the case of any such mutilation, on surrender and cancellation of this Warrant, the Company at its expense will execute and deliver, in lieu thereof, a new Warrant
of like tenor. 
 6. Negotiability, etc. This Warrant is issued upon the following terms, all of which the Holder hereof by the taking
hereof consents and agrees: 
 (a) The Holder shall not be entitled to pledge, mortgage, transfer, endorse or otherwise convey this Warrant
(a “Transfer’), in whole or in part, without with the prior written consent of the Company, other than to Affiliates (as defined below). To the extent permitted by the preceding sentence, the Holder and its direct and indirect transferees
may Transfer all or any portion of this Warrant by surrendering this Warrant to the Company together with a completed assignment in the form attached hereto as Annex B. Upon such surrender, the Company shall deliver a new Warrant or Warrants
to the person or persons entitled thereto and, if applicable, shall deliver to Holder a new Warrant evidencing the right of Holder to purchase the balance of the Warrant Shares subject to purchase hereunder. The term “Holder” as used
herein shall include any transferee to whom this Warrant has been Transferred in accordance with this Section 6. The term “Affiliate” as used herein means, with respect to any Holder, any other person or entity who, directly or
indirectly, controls, is controlled by, or is under common control with such Holder, including without limitation any general partner, managing member, limited partner, officer or director of such Holder or any venture capital fund now or hereafter
existing that is controlled by one or more general partners or managing members of, or shares the same management company with, such Holder. 

(b) The Holder shall not be entitled to vote or to receive dividends or to be deemed the Holder of capital stock that may at any time be
issuable upon exercise of this Warrant for any purpose whatsoever, nor shall anything contained herein be construed to confer upon the Holder any of the rights of a stockholder of the Company or any right to vote for the election of directors or
upon any matter submitted to stockholders at any meeting thereof, or to give or withhold consent to any corporate action (whether upon any recapitalization, issuance or reclassification of stock, change of par value or change of stock to no par
value, consolidation, merger or conveyance or otherwise), or to receive notice of meetings, or to receive dividends or subscription rights, until the Holder shall have exercised this Warrant and been issued shares of capital stock in accordance with
the provisions hereof. 
 (c) Neither this Warrant nor any shares of capital stock or other securities purchased pursuant to this Warrant
have been registered under the Securities Act and applicable state securities laws. Therefore, the transfer or exchange of this Warrant or such shares may be made only in a transaction permitted under the Securities Act and applicable state
securities laws or pursuant to an exemption therefrom. Prior to registration, the certificates evidencing the Warrant Shares or other securities issued on the exercise of this Warrant shall bear a legend to the effect that the shares evidenced by
such certificates have not been registered under the Securities Act and applicable state securities laws. 

  
 4 

 (d) Until this Warrant is transferred on the books of the Company, the Company may treat the
registered Holder hereof as the absolute owner hereof for all purposes, notwithstanding any notice to the contrary. 
 7. Notices,
etc. All notices and other communications from the Company to the Holder of this Warrant shall be sent by electronic transmission or overnight courier or shall be mailed by first class registered or certified mail, postage prepaid, at such
address as may have been furnished to the Company in writing by such Holder or, until any such Holder furnishes to the Company an address, then to, and at the address of, the last Holder of this Warrant who has so furnished an address to the
Company. All such notices and communications shall, when mailed, be effective when deposited in the mails and, when sent by electronic transmission or overnight courier, delivered, be effective when received. 

8. Amendments. This Warrant and any term hereof may be changed, waived, discharged or terminated only by an instrument in writing signed
by the party against which enforcement of such change, waiver, discharge or termination is sought. 
 9. Governing Law. This Warrant
shall be construed and enforced in accordance with and governed by the laws of the State of Delaware without regard to the laws that might be applied under any conflict of laws principles. 

10. Headings. The headings in this Warrant are for purposes of reference only, and shall not limit or otherwise affect any of the terms
hereof. 
 11. Severability. The invalidity or unenforceability of any provision hereof shall in no way affect the validity or
enforceability of any other provision. 
 12. Assumption of Warrant. Subject to Section 1(f), if at any time while this Warrant,
or any portion thereof, is outstanding and unexpired there shall be a Corporate Transaction, then, as a part of such transaction, the Company shall provide notice to the Holder prior to the closing of such Corporate Transaction and lawful provision
shall be made so that the Holder shall be entitled to receive upon exercise of this Warrant, during the period specified herein and upon payment of the Exercise Price then in effect, the number of shares of stock or other securities or property of
the successor corporation resulting from the Corporate Transaction which a holder of the shares deliverable upon exercise of this Warrant would have been entitled to receive in such Corporate Transaction if this Warrant had been exercised
immediately before such Corporate Transaction, all subject to adjustment as provided in Section 3. If the Holder does not exercise this Warrant pursuant to this Section 12 prior to the closing of a Corporate Transaction, then
Section 1(f) shall apply. 
 [END OF TEXT. SIGNATURE PAGE FOLLOWS.] 

  
 5 

 IN WITNESS WHEREOF, the Company has caused this Warrant to be executed by a duly authorized
officer as of the date first written above. 
  

			
	CENTREXION CORPORATION
		
	By:	 	  

		 	 Name: Jeffrey Kindler
 Title: Chief Executive
Officer

 Annex A 

Form of Exercise Notice 
 (To be executed if
Holder desires to exercise the Warrants evidenced by this Warrant Certificate). 
 TO CENTREXION CORPORATION 

 

	 	☐	 The undersigned hereby (1) irrevocably elects to exercise
                     Warrant Shares represented by this Warrant to
purchase                     shares of Series      Preferred Stock issuable upon the exercise of such Warrant,
(2) makes payment in full of the aggregate Exercise Price for such Warrants by enclosure of a certified or bank cashier’s check therefor, upon condition that a new Warrant be issued for the balance of the Warrant Shares remaining, if any,
and (3) requests that a certificate for the shares of Series      Preferred Stock purchased hereunder be issued in the name of and delivered to: 

(Please print name and address) 
  

	 	☐	 The undersigned hereby elects to convert
                                         
        percent (            %) of the value of the Warrant pursuant to the provisions of Section 2 of the Warrant. 

If such number of Warrant Shares not be all of the Warrant Shares evidenced by this Warrant Certificate, a new Warrant for the balance remaining of such
Warrant Shares shall be registered in the name of and delivered to: 
 (Please print name and address) 

 

	
	 Dated:
                                         
       
  

Signature:
                                         
 

  
 7 

 Annex B 

Form of Assignment 
 (To be executed by the
registered Holder if such Holder desires to transfer the attached Warrant.) 
 FOR VALUE RECEIVED,
                                         
        hereby sells, assigns, and transfers
unto                                        
         a Warrant to purchase                      shares of
Series      Convertible Preferred Stock, par value $0.001 per share, of Centrexion Corporation, a Delaware corporation (the “Company’’), together with all right, title, and interest therein, and
does hereby irrevocably constitute and appoint                      attorney to transfer such Warrant on the books of the Company, with full
power of substitution. 
 The undersigned represents, unless the sale of this Warrant has been registered under the Securities Act of 1933,
as amended (the “Securities Act”), that the undersigned is acquiring such Warrant for its own account for investment and not with a view to or for sale in connection with any distribution thereof (except for any resale pursuant to a
Registration Statement under the Securities Act). 
  

	
	
Dated:                  
                          
  

	
Signature:                 
                     

  
 8EX-4.7

 Exhibit 4.7 

Schedule of Holders of 
 Warrants
to Purchase Series C Preferred Stock 
  

																	
	 Holder
	  	Number of
Shares	 	  	Exercise
Price	 	  	Issuance
Date	 	  	Expiration
Date	 
	 InterWest Partners IX, LP
	  	 	85,714	 	  	 	$1.75	 	  	 	3/1/2016	 	  	 	3/1/2021	 
	 Sol J. Barer
	  	 	5,714	 	  	 	$1.75	 	  	 	3/1/2016	 	  	 	3/1/2021	 
	 Jonathan G Davis Trust
	  	 	14,286	 	  	 	$1.75	 	  	 	3/1/2016	 	  	 	3/1/2021	 
	 David Pozen and Joanna Pozen, as Trustees of the Pozen Family 2016 Trust
	  	 	28,571	 	  	 	$1.75	 	  	 	3/1/2016	 	  	 	3/1/2021	 
	 MAI 2 LLC
	  	 	22,857	 	  	 	$1.75	 	  	 	3/1/2016	 	  	 	3/1/2021	 
	 Thomas Kempner
	  	 	11,429	 	  	 	$1.75	 	  	 	3/1/2016	 	  	 	3/1/2021	 
	 Carl M. Loeb Trustee Thomas Kempner
	  	 	11,429	 	  	 	$1.75	 	  	 	3/1/2016	 	  	 	3/1/2021	 
	 Robert Grinberg
	  	 	11,429	 	  	 	$1.75	 	  	 	3/1/2016	 	  	 	3/1/2021	 
	 Michael Dan
	  	 	4,286	 	  	 	$1.75	 	  	 	3/1/2016	 	  	 	3/1/2021	 
	 Denice Hill
	  	 	4,285	 	  	 	$1.75	 	  	 	8/6/2018	 	  	 	3/1/2021	 
	 Irrevocable Aloha Trust
	  	 	11,429	 	  	 	$1.75	 	  	 	3/1/2016	 	  	 	3/1/2021	 
	 EZ MM&B Holdings LLC
	  	 	11,429	 	  	 	$1.75	 	  	 	3/1/2016	 	  	 	3/1/2021	 
	 Aptorum Group Limited
	  	 	28,571	 	  	 	$1.75	 	  	 	3/1/2016	 	  	 	3/1/2021	 
	 Robert K Green TOD
	  	 	11,429	 	  	 	$1.75	 	  	 	3/1/2016	 	  	 	3/1/2021	 

																	
	 Stephen Meringoff
	  	 	28,571	 	  	$	1.75	 	  	 	3/1/2016	 	  	 	3/1/2021	 
	 MarketPlace Lofts L.P.
	  	 	42,857	 	  	$	1.75	 	  	 	3/1/2016	 	  	 	3/1/2021	 
	 GH Healthlink Capital
	  	 	171,429	 	  	$	1.75	 	  	 	3/1/2016	 	  	 	3/1/2021	 
	 Lawrence M Blatt Trust
	  	 	2,857	 	  	$	1.75	 	  	 	3/1/2016	 	  	 	3/1/2021	 
	 Dyke Rogers
	  	 	8,571	 	  	$	1.75	 	  	 	3/1/2016	 	  	 	3/1/2021	 
	 Robert and Marjie Kargman
	  	 	28,571	 	  	$	1.75	 	  	 	3/1/2016	 	  	 	3/1/2021	 
	 Irwin Blitt Rev Trust
	  	 	8,571	 	  	$	1.75	 	  	 	3/1/2016	 	  	 	3/1/2021	 
	 Diana and David Freshwater Trust
	  	 	8,571	 	  	$	1.75	 	  	 	3/1/2016	 	  	 	3/1/2021	 
	 DJ & J LLC
	  	 	3,800	 	  	$	1.75	 	  	 	3/1/2016	 	  	 	3/1/2021	 
	 Rudes GCT Investment Ptn.
	  	 	14,286	 	  	$	1.75	 	  	 	3/1/2016	 	  	 	3/1/2021	 
	 F3F SPA
	  	 	20,000	 	  	$	1.75	 	  	 	3/1/2016	 	  	 	3/1/2021	 
	 InterWest Partners IX, LP
	  	 	85,714	 	  	$	1.75	 	  	 	4/8/2016	 	  	 	4/8/2021	 
	 River Charitable Remainder Trust
	  	 	5,714	 	  	$	1.75	 	  	 	4/8/2016	 	  	 	4/8/2021	 
	 Jeffrey B. Kindler
	  	 	5,714	 	  	$	1.75	 	  	 	4/8/2016	 	  	 	4/8/2021	 
	 AR Properties
	  	 	17,143	 	  	$	1.75	 	  	 	4/8/2016	 	  	 	4/8/2021	 
	 David Pyott Trust
	  	 	28,571	 	  	$	1.75	 	  	 	4/8/2016	 	  	 	4/8/2021	 
	 Transpac Investments Limited
	  	 	11,429	 	  	$	1.75	 	  	 	4/8/2016	 	  	 	4/8/2021	 
	 RM Kargman Life Insurance Trust
	  	 	28,571	 	  	$	1.75	 	  	 	4/8/2016	 	  	 	4/8/2021	 

  
 2 

																	
	 Kargman Rev Trust
	  	 	28,571	 	  	$	1.75	 	  	 	4/8/2016	 	  	 	4/8/2021	 
	 David Schwartz
	  	 	5,714	 	  	$	1.75	 	  	 	4/8/2016	 	  	 	4/8/2021	 
	 KF Business Ventures
	  	 	114,286	 	  	$	1.75	 	  	 	4/8/2016	 	  	 	4/8/2021	 
	 Mark Rubin
	  	 	5,714	 	  	$	1.75	 	  	 	4/8/2016	 	  	 	4/8/2021	 
	 Matthew Orlando
	  	 	1,429	 	  	$	1.75	 	  	 	4/8/2016	 	  	 	4/8/2021	 
	 Donald Fishbein
	  	 	2,857	 	  	$	1.75	 	  	 	4/8/2016	 	  	 	4/8/2021	 
	 Peter Friedland
	  	 	2,857	 	  	$	1.75	 	  	 	4/8/2016	 	  	 	4/8/2021	 
	 William Strawbridge
	  	 	1,429	 	  	$	1.75	 	  	 	4/8/2016	 	  	 	4/8/2021	 
	 INSYS Therapeutics, Inc.
	  	 	28,571	 	  	$	1.75	 	  	 	4/8/2016	 	  	 	4/8/2021	 
	 Henry Morris Zachs
	  	 	8,571	 	  	$	1.75	 	  	 	4/8/2016	 	  	 	4/8/2021	 
	 ACB Holdings
	  	 	1,429	 	  	$	1.75	 	  	 	4/8/2016	 	  	 	4/8/2021	 
	 Notas Family Trust
	  	 	3,429	 	  	$	1.75	 	  	 	4/8/2016	 	  	 	4/8/2021	 
	 Jonathan Perelman
	  	 	1,143	 	  	$	1.75	 	  	 	4/8/2016	 	  	 	4/8/2021	 
	 Robert Green Trust
	  	 	5,714	 	  	$	1.75	 	  	 	4/8/2016	 	  	 	4/8/2021	 
	 James Campbell Regina Anderson
	  	 	2,857	 	  	$	1.75	 	  	 	4/29/2016	 	  	 	4/29/2021	 
	 Mahyar Eidgah
	  	 	1,429	 	  	$	1.75	 	  	 	4/29/2016	 	  	 	4/29/2021	 
	 Roger Lash Rev Living Trust
	  	 	1,429	 	  	$	1.75	 	  	 	4/29/2016	 	  	 	4/29/2021	 
	 Rick Mace
	  	 	1,714	 	  	$	1.75	 	  	 	4/29/2016	 	  	 	4/29/2021	 

  
 3 

																	
	 Garfinkle Trust – Morris Garfinkle
	  	 	1,429	 	  	$	1.75	 	  	 	4/29/2016	 	  	 	4/29/2021	 
	 Lisa Rudes Grandchildren Trust
	  	 	14,286	 	  	$	1.75	 	  	 	4/29/2016	 	  	 	4/29/2021	 
	 Lawrence D Stern Annuity Trust
	  	 	28,571	 	  	$	1.75	 	  	 	4/29/2016	 	  	 	4/29/2021	 
	 BES Investments
	  	 	4,286	 	  	$	1.75	 	  	 	4/29/2016	 	  	 	4/29/2021	 
	 Marc Cohen
	  	 	1,714	 	  	$	1.75	 	  	 	4/29/2016	 	  	 	4/29/2021	 
	 Gary Ferman
	  	 	2,857	 	  	$	1.75	 	  	 	4/29/2016	 	  	 	4/29/2021	 
	 James and Arlene Payne
	  	 	17,143	 	  	$	1.75	 	  	 	4/29/2016	 	  	 	4/29/2021	 
	 Jim Aukstuolis
	  	 	1,714	 	  	$	1.75	 	  	 	4/29/2016	 	  	 	4/29/2021	 
	 Robert James Brickley
	  	 	1,429	 	  	$	1.75	 	  	 	4/29/2016	 	  	 	4/29/2021	 
	 Steven Glassman
	  	 	1,429	 	  	$	1.75	 	  	 	6/14/2016	 	  	 	6/14/2021	 
	 Shanghai Healthcare Industry
	  	 	571,429	 	  	$	1.75	 	  	 	6/14/2016	 	  	 	6/14/2021	 
	 Blairoma LLC
	  	 	65,057	 	  	$	1.75	 	  	 	6/14/2016	 	  	 	6/14/2021	 
	 TOTAL
	  	 	1,714,285	 	  				  				  			

  
 4 

 THIS WARRANT AND THE SECURITIES ISSUABLE UPON THE EXERCISE HEREOF HAVE
NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED. THEY MAY NOT BE SOLD, OFFERED FOR SALE, PLEDGED, HYPOTHECATED, OR OTHERWISE TRANSFERRED EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933, AS
AMENDED OR AN OPINION OF COUNSEL SATISFACTORY TO THE COMPANY THAT REGISTRATION IS NOT REQUIRED. 
  

 
 CENTREXION
THERAPEUTICS CORPORATION 
 WARRANT TO PURCHASE SHARES 

This Warrant is issued to
                                         
    by Centrexion Therapeutics Corporation, a Delaware corporation (the “Company”), pursuant to the terms of that certain Note and Warrant Purchase Agreement (the “Note Purchase Agreement”) of even
date herewith, in connection with the Company’s issuance to the holder of this Warrant of a Subordinated Convertible Promissory Note (the “Note”). 

1.    Purchase of Shares. Subject to the terms and conditions hereinafter set forth and set forth in the Note
Purchase Agreement, the holder of this Warrant is entitled, upon surrender of this Warrant at the principal office of the Company (or at such other place as the Company shall notify the holder hereof in writing), to purchase from the Company up to
the number of fully paid and nonassessable Shares (as defined below), that equals the quotient obtained by dividing (a) the Warrant Coverage Amount (as defined below) by (b) the Exercise Price (as defined below). 

2.    Definitions. 

(a)    Change of Control. The term “Change of Control” shall mean (i) the acquisition of the
Company by another entity by means of any transaction or series of related transactions with the Company (including, without limitation, any stock purchase, reorganization, merger or consolidation but, excluding any merger effected exclusively for
the purpose of changing the domicile of the Company); or (ii) a sale of all or substantially all of the assets of the Company, unless the Company’ stockholders of record as constituted immediately prior to such acquisition or sale
will, immediately after such acquisition or sale (solely by virtue of securities issued as consideration for the Company’s acquisition or sale or otherwise) hold at least 50% of the voting power of the surviving or acquiring entity. 

(b)    Exercise Price. The exercise price for the Shares shall be $1.75 per share, as adjusted for any stock
splits, dividends, combinations and the like (such price, as adjusted from time to time, is herein referred to as the “Exercise Price”). 

  
 5 

 (c)    Initial Public Offering. The term “Initial Public
Offering” shall mean an initial underwritten public offering of the Company’s common stock, par value $0.001 per share (“Common Stock”), which results in gross proceeds of at least $20,000,000. 

(d)    Non-Qualified Financing. The term “Non-Qualified Financing” shall mean a financing occurring prior to a Qualified Financing or a Change of Control pursuant to which the Company sells shares of its Common Stock or preferred stock of the
Company (“Preferred Stock”) in a financing other than a Qualified Financing or an Initial Public Offering, and in connection with which the holders of a majority of the outstanding principal amount under the Notes elect by written consent
to convert such Notes into shares of the Company’s securities issued in such Non-Qualified Financing. 

(e)    Qualified Financing. The term “Qualified Financing” shall mean an equity financing
occurring prior to a Change of Control pursuant to which the Company sells shares of its Common Stock or Preferred Stock (or convertible debt securities or, if approved by the holders of a majority of the aggregate outstanding amount under the
Notes, non-convertible debt securities) at a fully-diluted pre-money valuation of at least $75,000,000 and with aggregate gross proceeds to the Company of not less than
$10,000,000. 
 (f)    The Shares. The term “Shares” shall mean shares of the class and series
of securities issued to investors in a Qualified Financing or a Non-Qualified Financing which occurs prior to a Change of Control. 

(g)    Warrant Coverage Amount. The term “Warrant Coverage Amount” shall mean that amount which
equals 10% of the principal amount of the Note. 
 3.    Change of Control. In the event of a Change of Control
prior to a Qualified Financing or a Non-Qualified Financing, then, subject to Section 3 of the subordination agreement agreed upon among the holder of this warrant, the Company and Silicon Valley Bank
(the “Subordination Agreement”), the holder of this Warrant will be entitled to receive in cash the amount they would have received upon consummation of such Change of Control if this Warrant had been exercised for shares of the
Company’s Common Stock at the Exercise Price immediately prior thereto. 
 4.    Initial Public Offering. In
the event that prior to a Qualified Financing or a Non-Qualified Financing, the Company completes an Initial Public Offering and this Warrant has not yet been exercised, then this Warrant shall automatically,
without any further action on the part of the holder of this Warrant or the Company, be exercised on a cashless basis. The Company shall issue to the holder hereof a number of shares of Common Stock computed using the following formula: 

X = Y (A - B) 
 A 

  
 6 

 Where 
  

	 	X —	 The number of shares of Common Stock to be issued to the holder of this Warrant. 

 

	 	Y —	 The number of shares of Common Stock purchasable under this Warrant which equals (a) the Warrant Coverage
Amount divided by (b) the Exercise Price. 

  

	 	A —	 The price to the public per share of Common Stock on the cover of the final prospectus for the Initial Public
Offering. 

  

	 	B —	 The Exercise Price (as adjusted to the date of such calculations). 

5.    Exercise. (a) Method of Exercise. While this Warrant remains outstanding and exercisable in
accordance with Section 2 above, the holder may exercise, in whole or in part, the purchase rights evidenced hereby. Such exercise shall be effected by: 

(i)    the surrender of the Warrant, together with a notice of exercise to the Secretary of the Company at its principal
offices; and 
 (ii)    the payment to the Company of an amount equal to the aggregate Exercise Price for the number of
Shares being purchased. 
 (b)    Exercise Period. This Warrant shall be exercisable, in whole or in part, during
the term commencing on the closing date of a Qualified Financing or a Non-Qualified Financing (as defined below) or an Initial Public Offering and ending on the expiration of this Warrant pursuant to
Section 15 hereof. 
 6.    Certificates for Shares. Upon the exercise of the purchase rights evidenced by
this Warrant, one or more certificates for the number of Shares so purchased shall be issued as soon as practicable thereafter, and in any event within thirty (30) days of the delivery of the subscription notice. 

7.    Issuance of Shares. The Company covenants that the Shares, when issued pursuant to the exercise of this
Warrant, will be duly and validly issued, fully paid and nonassessable and free from all taxes, liens, and charges with respect to the issuance thereof. 

8.    Adjustment of Exercise Price and Number of Shares. The number of and kind of securities purchasable upon
exercise of this Warrant and the Exercise Price shall be subject to adjustment from time to time as follows: 

(a)    Subdivisions, Combinations and Other Issuances. If the Company shall at any time prior to the expiration of
this Warrant subdivide the Shares, by split-up or otherwise, or combine its Shares, or issue additional shares of its Shares as a dividend, the number of Shares issuable on the exercise of this Warrant shall
forthwith be proportionately increased in the case of a subdivision or stock dividend, or proportionately decreased in the case of a combination. Appropriate adjustments shall also be made to the purchase price payable per share, but the aggregate
purchase price payable for the total number of Shares purchasable under this Warrant (as adjusted) shall remain the same. Any adjustment under this Section 8(a) shall become effective at the close of business on the date the subdivision or
combination becomes effective, or as of the record date of such dividend, or in the event that no record date is fixed, upon the making of such dividend. 

  
 7 

 (b)    Reclassification, Reorganization and Consolidation. In
case of any reclassification, capital reorganization, or change in the capital stock of the Company (other than as a result of a subdivision, combination, or stock dividend provided for in Section 8(a) above), then the Company shall make
appropriate provision so that the holder of this Warrant shall have the right at any time prior to the expiration of this Warrant to purchase, at a total price equal to that payable upon the exercise of this Warrant, the kind and amount of shares of
stock and other securities and property receivable in connection with such reclassification, reorganization, or change by a holder of the same number of Shares as were purchasable by the holder of this Warrant immediately prior to such
reclassification, reorganization, or change. In any such case appropriate provisions shall be made with respect to the rights and interest of the holder of this Warrant so that the provisions hereof shall thereafter be applicable with respect to any
shares of stock or other securities and property deliverable upon exercise hereof, and appropriate adjustments shall be made to the purchase price per share payable hereunder, provided the aggregate purchase price shall remain the same. 

(c)    Notice of Adjustment. When any adjustment is required to be made in the number or kind of shares purchasable
upon exercise of the Warrant, or in the Exercise Price, the Company shall promptly notify the holder of such event and of the number of Shares or other securities or property thereafter purchasable upon exercise of this Warrant. 

9.    No Fractional Shares or Scrip. No fractional shares or scrip representing fractional shares shall be issued
upon the exercise of this Warrant, but in lieu of such fractional shares the Company shall make a cash payment therefor on the basis of the Exercise Price then in effect. 

10.    Representations of the Company. The Company represents that all corporate actions on the part of the
Company, its officers, directors and stockholders necessary for the sale and issuance of this Warrant have been taken. 

11.    Representations and Warranties by the Holder. The Holder represents and warrants to the Company as follows:

 (a)    This Warrant and the Shares issuable upon exercise thereof are being acquired for its own account, for
investment and not with a view to, or for resale in connection with, any distribution or public offering thereof within the meaning of the Securities Act of 1933, as amended (the “Act”). Upon exercise of this Warrant, the
Holder shall, if so requested by the Company, confirm in writing, in a form satisfactory to the Company, that the securities issuable upon exercise of this Warrant are being acquired for investment and not with a view toward distribution or resale.

 (b)    The Holder understands that the Warrant and the Shares have not been registered under the Act by reason of
their issuance in a transaction exempt from the registration and prospectus delivery requirements of the Act pursuant to Section 4(a)(2) thereof, and that they must be held by the Holder indefinitely, and that the Holder must therefore bear the
economic risk of such investment indefinitely, unless a subsequent disposition thereof is registered under the Act or is exempted from such registration. 

  
 8 

 (c)    The Holder has such knowledge and experience in financial and
business matters that it is capable of evaluating the merits and risks of the purchase of this Warrant and the Shares purchasable pursuant to the terms of this Warrant and of protecting its interests in connection therewith. 

(d)    The Holder is able to bear the economic risk of the purchase of the Shares pursuant to the terms of this Warrant.

 (e)    The Holder is an “accredited investor” as such term is defined in Rule 501 of Regulation D
promulgated under the Act. 
 12.    Restrictive Legend. 

The Shares (unless registered under the Act) shall be stamped or imprinted with a legend in substantially the following form: 

THE SHARES REPRESENTED BY THIS CERTIFICATE HAVE BEEN ACQUIRED FOR INVESTMENT AND NOT WITH A VIEW TO, OR IN CONNECTION WITH, THE SALE OR
DISTRIBUTION THEREOF, AND HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED. SUCH SHARES MAY NOT BE SOLD OR TRANSFERRED IN THE ABSENCE OF SUCH REGISTRATION OR AN EXEMPTION THEREFROM UNDER THE ACT AND ANY APPLICABLE STATE
SECURITIES LAWS. COPIES OF THE AGREEMENT COVERING THE PURCHASE OF THESE SHARES AND RESTRICTING THEIR TRANSFER MAY BE OBTAINED AT NO COST BY WRITTEN REQUEST MADE BY THE HOLDER OF RECORD OF THIS CERTIFICATE TO THE SECRETARY OF THE COMPANY AT THE
PRINCIPAL EXECUTIVE OFFICES OF THE COMPANY. 
 13.    Warrants Transferable. Subject to compliance with the terms
and conditions of this Section 13, this Warrant and all rights hereunder are transferable, in whole or in part, without charge to the holder hereof (except for transfer taxes), upon surrender of this Warrant properly endorsed or accompanied by
written instructions of transfer. With respect to any offer, sale or other disposition of this Warrant or any Shares acquired pursuant to the exercise of this Warrant prior to registration of such Warrant or Shares, the holder hereof agrees to give
written notice to the Company prior thereto, describing briefly the manner thereof, together with a written opinion of such holder’s counsel, or other evidence, if requested by the Company, to the effect that such offer, sale or other
disposition may be effected without registration or qualification (under the Act as then in effect or any federal or state securities law then in effect) of this Warrant or the Shares and indicating whether or not under the Act certificates for this
Warrant or the Shares to be sold or otherwise disposed of require any restrictive legend as to applicable restrictions on transferability in order to ensure 

  
 9 

 
compliance with such law. Upon receiving such written notice and reasonably satisfactory opinion or other evidence, if so requested, the Company, as promptly as practicable, shall notify such
holder that such holder may sell or otherwise dispose of this Warrant or such Shares, all in accordance with the terms of the notice delivered to the Company. If a determination has been made pursuant to this Section 13 that the opinion of
counsel for the holder or other evidence is not reasonably satisfactory to the Company, the Company shall so notify the holder promptly with details thereof after such determination has been made. Each certificate representing this Warrant or the
Shares transferred in accordance with this Section 13 shall bear a legend as to the applicable restrictions on transferability in order to ensure compliance with such laws, unless in the aforesaid opinion of counsel for the holder, such legend
is not required in order to ensure compliance with such laws. The Company may issue stop transfer instructions to its transfer agent in connection with such restrictions. 

14.    Rights of Stockholders. No holder of this Warrant shall be entitled, as a Warrant holder, to vote or receive
dividends or be deemed the holder of the Shares or any other securities of the Company which may at any time be issuable on the exercise hereof for any purpose, nor shall anything contained herein be construed to confer upon the holder of this
Warrant, as such, any of the rights of a stockholder of the Company or any right to vote for the election of directors or upon any matter submitted to stockholders at any meeting thereof, or to give or withhold consent to any corporate action
(whether upon any recapitalization, issuance of stock, reclassification of stock, change of par value, consolidation, merger, conveyance, or otherwise) or to receive notice of meetings, or to receive dividends or subscription rights or otherwise
until the Warrant shall have been exercised and the Shares purchasable upon the exercise hereof shall have become deliverable, as provided herein. 

15.    Expiration of Warrant; Notice of Certain Events Terminating This Warrant. 

(a)    This Warrant shall expire and shall no longer be exercisable upon the earlier to occur of: 

(i)    The date that is five years from the original issue date of this Warrant; 

(ii)    The closing of an Initial Public Offering; or 

(iii)    Any Change of Control. 

(b)    The Company shall provide at least ten (10) days prior written notice of any event set forth in
Section 15(a). 
 16.    Notices. All notices and other communications required or permitted hereunder shall
be in writing, shall be effective when given, and shall in any event be deemed to be given upon receipt or, if earlier, (a) five (5) days after deposit with the U.S. Postal Service or other applicable postal service, if delivered by first
class mail, postage prepaid, (b) upon delivery, if delivered by hand, (c) one business day after the business day of deposit with Federal Express or similar overnight courier, freight prepaid or (d) one business day after the business
day of facsimile transmission, if 

  
 10 

 
delivered by facsimile transmission with copy by first class mail, postage prepaid, and shall be addressed (i) if to the Holder, at the Holder’s address as set forth on the Schedule of
Investors to the Note Purchase Agreement, and (ii) if to the Company, at the address of its principal corporate offices (attention: President), or at such other address as a party may designate by ten days advance written notice to the other
party pursuant to the provisions above. 
 17.    “Market
Stand-Off” Agreement. The Holder hereby agrees that, during the period of duration specified by the Company and an underwriter of common stock or other securities of the Company, following the
effective date of a registration statement of the Company filed under the Act, it shall not, to the extent requested by the Company and such underwriter, directly or indirectly sell, offer to sell, contract to sell (including, without limitation,
any short sale), grant any option to purchase or otherwise transfer or dispose of (other than to donees who agree to be similarly bound) any securities of the Company held by it at any time during such period except common stock included in such
registration; provided, however, that: 
 (a)    all officers and directors of the Company and all other
persons with registration rights (whether or not pursuant to this Agreement) enter into similar agreements; 

(b)    the Company obtains from persons who hold two percent (2%) or greater of the Company’s outstanding capital
stock, a lock-up agreement similar to that set forth in this Section 17; and 

(c)    such market stand-off time period shall not exceed one hundred eighty
(180) days for the Company’s initial public offering, and ninety (90) days for any subsequent public offerings. 
 Holder
agrees to provide to the other underwriters of any public offering such further agreements as such underwriter may reasonably request in connection with this market stand-off agreement, provided that the terms
of such agreements are substantially consistent with the provisions of this Section 17. In order to enforce the foregoing covenant, the Company may impose stop-transfer instructions with respect to the Registrable Securities of each Holder (and
the shares or securities of every other person subject to the foregoing restriction) until the end of such period. 
 Notwithstanding the
foregoing, the obligations described in this Section 17 shall not apply to a registration relating solely to employee benefit plans on Form S-8 or a similar form which may be promulgated in the future, or
a registration relating solely to an SEC Rule 145 transaction. 
 18.    Registration Rights Agreement. The
registration rights of the Holder (including Holders’ successors) with respect to the Common Stock issuable upon exercise of this Warrant, or, if this Warrant is exercisable for convertible securities, upon conversion of such securities, will
be the same as those granted to the holders of Shares issued in the Qualified Financing. 
 19.    Governing Law.
This Warrant and all actions arising out of or in connection with this Agreement shall be governed by and construed in accordance with the laws of the State of New York, without regard to the conflicts of law provisions of the State of New York or
of any other state. 

  
 11 

 20.    Rights and Obligations Survive Exercise of Warrant. Unless
otherwise provided herein, the rights and obligations of the Company, of the holder of this Warrant and of the holder of the Shares issued upon exercise of this Warrant, shall survive the exercise of this Warrant. 

[Signature page follows] 

  
 12 

 Issued this
                                        .

  

			
	CENTREXION THERAPEUTICS CORPORATION

 
			
		
	By:	 	 

 
			
		
	Title:	 	 

  
 13 

 EXHIBIT A 

NOTICE OF EXERCISE 
  

					
	TO:	 	CENTREXION THERAPEUTICS CORPORATION
			
		 	 	 	
			
		 	 	 	
		 	Attention: President	 	

 1.    The undersigned hereby elects to purchase
                         shares of
                         pursuant to the terms of the attached Warrant. 

2.    Method of Exercise (Please initial the applicable blank): 

 

	 	—	 The undersigned elects to exercise the attached Warrant by means of a cash payment, and tenders herewith
payment in full for the purchase price of the shares being purchased, together with all applicable transfer taxes, if any. 

  

	 	—	 The undersigned elects to exercise the attached Warrant by means of the net exercise provisions of
Section 4 of the Warrant. 

 3.    Please issue a certificate or certificates representing said
Shares in the name of the undersigned or in such other name as is specified below: 
  

					
			
		 	 	 	
		 	(Name)	 	
			
		 	 	 	
			
		 	 	 	
		 	(Address)	 	

 4.    The undersigned hereby represents and warrants that the aforesaid Shares are being
acquired for the account of the undersigned for investment and not with a view to, or for resale, in connection with the distribution thereof, and that the undersigned has no present intention of distributing or reselling such shares and all
representations and warranties of the undersigned set forth in Section 11 of the attached Warrant (including Section 11(e) thereof) are true and correct as of the date hereof. 

 

					
		 		 	 
		 		 	(Signature)
			
		 		 	 
		 		 	(Name)
			
	 	 		 	 
	(Date)	 		 	(Title)

 EXHIBIT B 

FORM OF TRANSFER 
 (To be
signed only upon transfer of Warrant) 
 FOR VALUE RECEIVED, the undersigned hereby sells, assigns and transfers unto
                                         
                                the right represented by the attached Warrant to purchase
                                     shares of
                                         
        of Centrexion Therapeutics Corporation to which the attached Warrant relates, and appoints
                                 Attorney to transfer such right on the books of
                            , with full power of substitution in the premises. 

 

			
	Dated:	 	 

  

			
	
	 
	(Signature must conform in all respects to name of Holder as specified on the face of the Warrant)
		
	Address:	 	 
		
		 	 
		
		 	 

  

	
	Signed in the presence of:

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00288-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00288-of-00352.parquet"}]]